JP7093311B2 - ペグ化ブタインターフェロンおよびその使用方法 - Google Patents

ペグ化ブタインターフェロンおよびその使用方法 Download PDF

Info

Publication number
JP7093311B2
JP7093311B2 JP2018566519A JP2018566519A JP7093311B2 JP 7093311 B2 JP7093311 B2 JP 7093311B2 JP 2018566519 A JP2018566519 A JP 2018566519A JP 2018566519 A JP2018566519 A JP 2018566519A JP 7093311 B2 JP7093311 B2 JP 7093311B2
Authority
JP
Japan
Prior art keywords
pinf
mutant
pig
variant
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018566519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519553A (ja
JP2019519553A5 (enExample
Inventor
ピーター・コナー・カニング
ニコラス・ヌードセン
リリアン・スキッドモア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ambrx Inc
Elanco US Inc
Original Assignee
Ambrx Inc
Elanco US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc, Elanco US Inc filed Critical Ambrx Inc
Publication of JP2019519553A publication Critical patent/JP2019519553A/ja
Publication of JP2019519553A5 publication Critical patent/JP2019519553A5/ja
Priority to JP2022098147A priority Critical patent/JP7441892B2/ja
Application granted granted Critical
Publication of JP7093311B2 publication Critical patent/JP7093311B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2018566519A 2016-06-20 2017-06-16 ペグ化ブタインターフェロンおよびその使用方法 Active JP7093311B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022098147A JP7441892B2 (ja) 2016-06-20 2022-06-17 ペグ化ブタインターフェロンおよびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662352163P 2016-06-20 2016-06-20
US62/352,163 2016-06-20
PCT/US2017/037964 WO2017222940A1 (en) 2016-06-20 2017-06-16 Pegylated porcine interferon and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022098147A Division JP7441892B2 (ja) 2016-06-20 2022-06-17 ペグ化ブタインターフェロンおよびその使用方法

Publications (3)

Publication Number Publication Date
JP2019519553A JP2019519553A (ja) 2019-07-11
JP2019519553A5 JP2019519553A5 (enExample) 2020-01-30
JP7093311B2 true JP7093311B2 (ja) 2022-06-29

Family

ID=59258379

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018566519A Active JP7093311B2 (ja) 2016-06-20 2017-06-16 ペグ化ブタインターフェロンおよびその使用方法
JP2022098147A Active JP7441892B2 (ja) 2016-06-20 2022-06-17 ペグ化ブタインターフェロンおよびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022098147A Active JP7441892B2 (ja) 2016-06-20 2022-06-17 ペグ化ブタインターフェロンおよびその使用方法

Country Status (17)

Country Link
US (2) US10960080B2 (enExample)
EP (1) EP3471755B1 (enExample)
JP (2) JP7093311B2 (enExample)
KR (2) KR102518451B1 (enExample)
CN (2) CN109641034B (enExample)
AU (2) AU2017280958A1 (enExample)
CA (1) CA3028683A1 (enExample)
CL (1) CL2018003697A1 (enExample)
DK (1) DK3471755T3 (enExample)
EA (1) EA036509B1 (enExample)
ES (1) ES2793773T3 (enExample)
MX (1) MX391970B (enExample)
NZ (1) NZ749962A (enExample)
PL (1) PL3471755T3 (enExample)
PT (1) PT3471755T (enExample)
WO (1) WO2017222940A1 (enExample)
ZA (1) ZA201808352B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (en) 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
EP4223369A1 (en) 2016-12-22 2023-08-09 Incyte Corporation Immunomodulator compounds and methods of use
SMT202300065T1 (it) 2018-03-30 2023-05-12 Incyte Corp Composti eterociclici come immunomodulatori
CN112752756B (zh) 2018-05-11 2024-06-25 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
TW202115059A (zh) 2019-08-09 2021-04-16 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽
CN110343164A (zh) * 2019-08-22 2019-10-18 安阳工学院 一种高活性7位点突变的猪干扰素α突变体及其制备方法和应用
JP7559059B2 (ja) 2019-09-30 2024-10-01 インサイト・コーポレイション 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物
EP4058461A1 (en) 2019-11-11 2022-09-21 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
IL302590A (en) 2020-11-06 2023-07-01 Incyte Corp Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
CN113845599B (zh) * 2021-11-01 2023-09-19 长春萤火虫生物科技有限公司 一种重组猪干扰素融合蛋白及其应用
WO2024241086A1 (en) 2023-05-24 2024-11-28 Ambrx, Inc. Pegylated bovine interferon lambda and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008541769A (ja) 2005-06-03 2008-11-27 アンブレツクス・インコーポレイテツド 改善されたヒトインターフェロン分子及びそれらの使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) * 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
HUT75533A (en) * 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US20050226845A1 (en) * 2004-03-10 2005-10-13 Chih-Ping Liu Method of treatment using interferon-tau
JP2006213597A (ja) 2000-07-19 2006-08-17 Pepgen Corp インターフェロン−タウを用いるｃ型肝炎ウイルスの処置のための組成物およびモニタリングの方法
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US7695710B2 (en) * 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
CN101883784B (zh) 2007-10-01 2014-10-15 药华医药股份有限公司 N-端修饰的干扰素-α
EP2318029B1 (en) 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
CN104262480B (zh) * 2014-09-28 2018-03-27 重庆理工大学 重组猪长效‑α干扰素的构建和修饰方法及其冻干注射剂的制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008541769A (ja) 2005-06-03 2008-11-27 アンブレツクス・インコーポレイテツド 改善されたヒトインターフェロン分子及びそれらの使用

Also Published As

Publication number Publication date
JP2022137063A (ja) 2022-09-21
PT3471755T (pt) 2020-05-22
US20190192673A1 (en) 2019-06-27
AU2021229132B2 (en) 2023-04-06
EP3471755B1 (en) 2020-04-22
JP2019519553A (ja) 2019-07-11
CA3028683A1 (en) 2017-12-28
JP7441892B2 (ja) 2024-03-01
CL2018003697A1 (es) 2019-05-10
WO2017222940A1 (en) 2017-12-28
EP3471755A1 (en) 2019-04-24
AU2017280958A1 (en) 2018-12-20
PL3471755T3 (pl) 2020-10-19
KR20190039889A (ko) 2019-04-16
MX2018016295A (es) 2019-09-16
ES2793773T3 (es) 2020-11-16
AU2021229132A1 (en) 2021-09-30
CN109641034A (zh) 2019-04-16
KR102409470B1 (ko) 2022-06-16
KR102518451B1 (ko) 2023-04-04
CN109641034B (zh) 2023-08-15
NZ749962A (en) 2020-06-26
US10960080B2 (en) 2021-03-30
KR20220086700A (ko) 2022-06-23
CN117024562A (zh) 2023-11-10
ZA201808352B (en) 2020-08-26
MX391970B (es) 2025-03-21
BR112018076437A2 (pt) 2019-10-01
DK3471755T3 (da) 2020-05-18
US12653897B2 (en) 2026-06-16
EA201892671A1 (ru) 2019-05-31
EA036509B1 (ru) 2020-11-18
US20210177980A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
JP7441892B2 (ja) ペグ化ブタインターフェロンおよびその使用方法
KR20090089316A (ko) Ｐｅｇ 변형된 엑센딘 또는 엑센딘 유사체 및 조성물 및 이의 용도
BR112015011583B1 (pt) Métodos para aumentar o tamanho ou volume hidrodinâmico de hormônio de crescimento humano, método para aumentar o peso molecular aparente de um polipeptídeo e método para aumentar a meia-vida de um polipeptídeo
US10406235B2 (en) Use of multi-arm polyethylene glycol modifier and application of multi-arm polyethylene glycol modifier in L-asparaginasum modification
KR20150008137A (ko) 지속성 옥신토모둘린 변이체 및 이의 생산 방법
JP2019519553A5 (enExample)
US20120128629A1 (en) Method of labelling interferons with peg
JP2023540486A (ja) 免疫原性コロナウイルス融合タンパク質および関連方法
RU2488598C2 (ru) Гормон роста, модифицированный двухцепочечным полиэтиленгликолем, способ его получения и применение
KR20220125289A (ko) Fgf-21 접합체 제제
CN101671390B (zh) 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
EP3925617A1 (en) Recombinant protein for eliminating boar taint and vaccine composition comprising same
WO2005105151A1 (en) Pegylated thymosin 1 derivatives
WO2016140983A1 (en) Compositions and methods for pegylated il-11
US20240052330A1 (en) Blockade of sars-cov-2 infection using hydrocarbon stapled peptides
CN101385858B (zh) 纯化的peg化人生长激素缀合物及其药物制剂
WO2026055636A1 (en) Peptides and compositions for improving glucose levels
WO2024241086A1 (en) Pegylated bovine interferon lambda and methods of use thereof
HK40108760A (en) Therapeutic derivatives of interleukin-22

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220518

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220617

R150 Certificate of patent or registration of utility model

Ref document number: 7093311

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250